# PDUFA dates July 2025: FDA calendar and catalysts

Canonical: https://sec-api.dev/fda-calendar/2025-07

> 181 FDA catalysts are dated in July 2025, including 23 PDUFA dates.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What PDUFA dates are in July 2025?

PDUFA dates in July 2025: Lynozyfic (linvoseltamab, REGN) on July 10, 2025; Akebia Therapeutics, Inc. (AKBA) on July 15, 2025; Dyne Therapeutics, Inc. (DYN) on July 15, 2025; Beam Therapeutics Inc. (BEAM) on July 15, 2025; Trevi Therapeutics, Inc. (TRVI) on July 15, 2025; Kalaris Therapeutics, Inc. (KLRS) on July 15, 2025; and 17 more. [Calendar and source filings](https://sec-api.dev/fda-calendar/2025-07)

Source: Press release filed with the SEC (EX-99), accession 0001804220-25-000020, https://www.sec.gov/Archives/edgar/data/872589/000180422025000020/exhibit991q12025.htm (retrieved 2026-11-12). Last confirmed 2025-04-29. Cite: https://sec-api.dev/fda-calendar/2025-07#answer

## PDUFA dates in July 2025

Data as of November 16, 2026.

| PDUFA date | Company | Ticker | Drug | Indication | Source |
| --- | --- | --- | --- | --- | --- |
| July 10, 2025 | REGENERON PHARMACEUTICALS, INC. | REGN | Lynozyfic (linvoseltamab) |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/872589/000180422025000020/exhibit991q12025.htm) |
| July 15, 2025 | Akebia Therapeutics, Inc. | AKBA |  |  | [SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1517022/000151702226000039/akba-20260331.htm) |
| July 15, 2025 | Dyne Therapeutics, Inc. | DYN |  |  | [SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1818794/000095017025099161/dyn-20250630.htm) |
| July 15, 2025 | Beam Therapeutics Inc. | BEAM |  |  | [SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1745999/000095017025102393/beam-20250630.htm) |
| July 15, 2025 | Trevi Therapeutics, Inc. | TRVI |  |  | [SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1563880/000095017025105066/trvi-20250630.htm) |
| July 15, 2025 | Kalaris Therapeutics, Inc. | KLRS |  |  | [SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1754068/000095017025107979/klrs-20250630.htm) |
| July 15, 2025 | KALA BIO, Inc. | KALA |  |  | [SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1479419/000155837025010853/kala-20250630x10q.htm) |
| July 15, 2025 | ARVINAS, INC. | ARVN |  |  | [SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1655759/000165575925000139/arvn-20250630.htm) |
| July 15, 2025 | CURIS INC | CRIS |  |  | [SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1108205/000110820525000080/cris-20250630.htm) |
| July 15, 2025 | Climb Bio, Inc. | CLYM |  |  | [SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1768446/000095017025106916/clym-20250630.htm) |
| July 15, 2025 | Spero Therapeutics, Inc. | SPRO |  |  | [SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1701108/000095017025107388/spro-20250630.htm) |
| July 15, 2025 | Schrodinger, Inc. | SDGR |  |  | [SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1490978/000149097826000076/sdgr-20260930.htm) |
| July 22, 2025 | Replimune Group, Inc. | REPL |  |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1737953/000110465925005291/tm254066d1_ex99-1.htm) |
| July 22, 2025 | Replimune Group, Inc. | REPL | Opdivo® (nivolumab) |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1737953/000110465925011851/tm256243d1_ex99-1.htm) |
| July 23, 2025 | GSK plc | GSK |  |  | [SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1131399/000165495425001166/finalresults05-0225.htm) |
| July 27, 2025 | Royalty Pharma plc | RPRX |  |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1802768/000119312525023988/d929959dex991.htm) |
| July 27, 2025 | Ascendis Pharma A/S | ASND | SKYTROFA (lonapegsomatropin) | with GHD | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1612042/000119312525004905/d923527dex991.htm) |
| July 29, 2025 | PTC THERAPEUTICS, INC. | PTCT | Kebilidi (eladocagene exuparvovec) | AADC deficiency | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1070081/000107008125000011/tmb-20250227xex99d1.htm) |
| July 29, 2025 | Cingulate Inc. | CING |  |  | [SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1862150/000164117225024744/form10-q.htm) |
| July 29, 2025 | PTC THERAPEUTICS, INC. | PTCT | Sephience™ (sepiapterin) |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1070081/000107008125000018/tmb-20250506xex99d1.htm) |
| July 30, 2025 | Coya Therapeutics, Inc. | COYA |  |  | [SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1835022/000119312525168115/d14950d8k.htm) |
| July 30, 2025 | REGENERON PHARMACEUTICALS, INC. | REGN | Ordspono™ (odronextamab) |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/872589/000180422025000020/exhibit991q12025.htm) |
| July 30, 2025 | REGENERON PHARMACEUTICALS, INC. | REGN |  |  | [SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/872589/000180422025000022/regn-20250331.htm) |

## All catalysts in July 2025

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| July 1, 2025 | [Kisunla (donanemab-azbt) label expansion decision](https://sec-api.dev/pdufa/donanemab-azbt) | LLY |  | completed, approved | "BLA761248 SUPPL-4 (Efficacy): submission_status AP, submission_status_date 20250701, review_priority PRIORITY; sponsor_name ELI LILLY CO; product KISUNLA (DONANEMAB-AZBT)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761248%22)) |
| July 1, 2025 | [Entyvio® (vedolizumab) primary completion](https://sec-api.dev/pdufa/vedolizumab) | TAK | Colitis, Ulcerative | completed | "NCT04779307 (A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Ulcerative Colitis (UC)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-07-01 (ACTUAL); Lead Sponsor Takeda; Results First Posted 2026-04-30." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04779307)) |
| July 1, 2025 | [Telix Pharmaceuticals Ltd primary completion](https://sec-api.dev/companies/tlx/catalysts) | TLX | Metastatic Prostate Cancer | withdrawn | "NCT04876651 (The Present Study Aims to Compare Patients Who Receive the Investigational Product (177Lu-DOTA-rosopatamab) Plus Standard of Care, in Comparison to Standard of Care Only): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-07-01 (ACTUAL); Lead Sponsor Telix Pharmaceuticals (Innovations) Pty Ltd." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04876651)) |
| July 2, 2025 | [Daxdilimab primary completion](https://sec-api.dev/pdufa/daxdilimab) | AMGN | Idiopathic Inflammatory Myositis | completed | "NCT05669014 (A Phase 2 Proof of Concept Study to Evaluate the Efficacy and Safety of Daxdilimab in Participants With Dermatomyositis (DM) or Anti-synthetase Inflammatory Myositis (ASIM)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-07-02 (ACTUAL); Lead Sponsor Amgen; Results First Posted 2026-08-25." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05669014)) |
| July 2, 2025 | [Efgartigimod iv primary completion](https://sec-api.dev/pdufa/efgartigimod-iv) | ARGX | Lupus Nephritis | completed | "NCT05810948 (A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients With Lupus Nephritis (ZL-1103-013)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-07-02 (ACTUAL); Lead Sponsor argenx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05810948)) |
| July 3, 2025 | [TAR-200 primary completion](https://sec-api.dev/pdufa/tar-200) | JNJ | Urinary Bladder Neoplasms | completed | "NCT04640623 (A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2025-07-03 (ACTUAL); Lead Sponsor Janssen Research & Development, LLC; Results First Posted 2026-07-29." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04640623)) |
| July 3, 2025 | [Lupkynis (voclosporin) primary completion](https://sec-api.dev/pdufa/voclosporin) | AUPH | Adolescent Lupus Nephritis; Pediatric Lupus Nephritis | withdrawn | "NCT05288855 (Voclosporin in Adolescent and Pediatric Subjects With Lupus Nephritis): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-07-03 (ACTUAL); Lead Sponsor Aurinia Pharmaceuticals Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05288855)) |
| July 3, 2025 | [Met097 injection primary completion](https://sec-api.dev/pdufa/met097) | PFE | Obesity; Overweight or Obesity | completed | "NCT06712836 (A Phase 2b Study to Examine the Safety and Efficacy of Once-Weekly MET097 in Adults With Obesity or Overweight): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-07-03 (ACTUAL); Lead Sponsor Pfizer; Results First Posted 2026-08-28." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06712836)) |
| July 4, 2025 | [Sacituzumab govitecan-hziy primary completion](https://sec-api.dev/pdufa/sacituzumab-govitecan-hziy) | GILD | Locally Advanced or Metastatic Unresectable Urothelial Cancer | completed | "NCT04527991 (Study of Sacituzumab Govitecan Versus Physician's Choice of Treatment in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-07-04 (ACTUAL); Lead Sponsor Gilead Sciences; Results First Posted 2026-06-02." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04527991)) |
| July 4, 2025 | [Lupkynis (voclosporin) primary completion](https://sec-api.dev/pdufa/voclosporin) | AUPH | Adolescent Lupus Nephritis; Pediatric Lupus Nephritis | withdrawn | "NCT05962788 (Long-Term Voclosporin Treatment in Adolescent and Pediatric Subjects With Lupus Nephritis): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-07-04 (ACTUAL); Lead Sponsor Aurinia Pharmaceuticals Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05962788)) |
| July 7, 2025 | [Tividenofusp alfa NDA/BLA acceptance](https://sec-api.dev/pdufa/tividenofusp-alfa) | DNLI | Hunter syndrome | completed | "SOUTH SAN FRANCISCO, Calif., - July 7, 2025 - Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) seeking accelerated approval for tividenofusp alfa for the treatment of Hunter syndrome (mucopolysaccharidoses type II, or MPS II), a rare and progressive genetic disorder." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1714899/000171489925000146/exhibit991pressrelease7720.htm)) |
| July 7, 2025 | [EP-104 trial start](https://sec-api.dev/pdufa/ep-104) | EPRX |  | completed | "The first patient was dosed in the randomized dose optimization portion of the study on July 7, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1581178/000119312526455405/d98561dex992.htm)) |
| July 7, 2025 | [Bezuclastinib topline data readout](https://sec-api.dev/pdufa/bezuclastinib) | COGT |  | completed, met | "On July 7, 2025, Cogent Biosciences, Inc. (the "Company") announced positive top-line results from the registration-directed Part 2 of the SUMMIT clinical trial of bezuclastinib in patients with non-advanced systemic mastocytosis ("NonAdvSM") demonstrating clinically meaningful and highly statistically significant improvements across the primary and all key secondary endpoints, including patient-reported symptoms and objective measures of mast cell burden." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1622229/000119312525155811/d156610d8k.htm)) |
| July 7, 2025 | [Pemazyre (pemigatinib) primary completion](https://sec-api.dev/pdufa/pemigatinib) | INCY | Unresectable Cholangiocarcinoma; Metastatic Cholangiocarcinoma | withdrawn | "NCT03656536 (A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-07-07 (ACTUAL); Lead Sponsor Incyte Corporation; Results First Posted 2026-08-11." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03656536)) |
| July 7, 2025 | [Exa-cel primary completion](https://sec-api.dev/pdufa/exa-cel) | VRTX | Sickle Cell Disease; Hematological Diseases; Hemoglobinopathies | completed | "NCT03745287 (A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell Disease): Overall Status COMPLETED; Phase PHASE2, PHASE3; Primary Completion 2025-07-07 (ACTUAL); Lead Sponsor Vertex Pharmaceuticals Incorporated; Results First Posted 2026-09-16." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03745287)) |
| July 7, 2025 | [Verekitug (upb-101) primary completion](https://sec-api.dev/pdufa/verekitug-upb-101) | UPB | Chronic Rhinosinusitis With Nasal Polyps | completed | "NCT06164704 (A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Participants With Chronic Rhinosinusitis With Nasal Polyps): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-07-07 (ACTUAL); Lead Sponsor Upstream Bio Inc.; Results First Posted 2026-09-18." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06164704)) |
| July 7, 2025 | [Qulipta (atogepant) primary completion](https://sec-api.dev/pdufa/atogepant) | ABBV | Migraine | completed | "NCT06241313 (Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraine): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-07-07 (ACTUAL); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06241313)) |
| July 7, 2025 | [FAYUVI (rebisufligene etisparvovec) complete response letter (CRL)](https://sec-api.dev/pdufa/rebisufligene-etisparvovec) | RARE |  | completed, complete response letter | "COMPLETE RESPONSE letter dated 07/07/2025 for BL 125845 to Ultragenyx Pharmaceutical Inc.." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_BLA125845_20250707.pdf%22)) |
| July 8, 2025 | [Lomecel-B (laromestrocel) FDA approval](https://sec-api.dev/pdufa/laromestrocel) | LGVN |  | completed, approved | "As announced on July 8, 2025, the FDA approved the Investigational New Drug (IND) application for our stem cell therapy laromestrocel as a potential treatment for pediatric Dilated Cardiomyopathy (DCM)." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1721484/000119312525264604/lgvn-20250930.htm)) |
| July 8, 2025 | [EUPRAXIA PHARMACEUTICALS INC. trial start](https://sec-api.dev/companies/eprx/catalysts) | EPRX |  | completed | "VICTORIA, British Columbia, July 08, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced the first patient dosed in the Phase 2b randomized, placebo-controlled portion of the RESOLVE clinical trial evaluating EP-104GI, an investigational treatment for eosinophilic esophagitis ("EoE")." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1581178/000117184325004357/exh_991.htm)) |
| July 8, 2025 | [ET-600 NDA/BLA acceptance](https://sec-api.dev/pdufa/et-600) | ETON |  | completed | "On July 8, 2025, Eton Pharmaceuticals, Inc. (the "Company") issued a press release announcing that the Company's New Drug Application for ET-600, a proprietary patented formulation of desmopressin oral solution, was accepted for review by the Food and Drug Administration (FDA) and assigned a Prescription Drug User Fee Administration target action date of February 25, 2026." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1710340/000143774925022298/eton20250702_8k.htm)) |
| July 8, 2025 | [REGEN-007 topline data readout](https://sec-api.dev/pdufa/regen-007) | PROK | CKD and diabetes | completed, met | "WINSTON-SALEM, N.C., July 8, 2025 - ProKidney Corp. (Nasdaq: PROK) ("ProKidney" or the "Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today reported statistically significant and clinically meaningful positive topline results from the full Group 1 modified intent-to-treat (mITT) population of the Phase 2 REGEN-007 trial evaluating rilparencel in patients with CKD and diabetes." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1850270/000095017025094445/prok-ex99_1.htm)) |
| July 8, 2025 | [Longeveron (longeveron) FDA approval](https://sec-api.dev/pdufa/longeveron) | LGVN |  | completed, approved | "Longeveron® Announces U.S. FDA Approval of IND Application for a Phase 2 Pivotal Registration Study" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1721484/000121390025062337/ea024838901ex99-1_longeveron.htm)) |
| July 8, 2025 | [Tecfidera (dimethyl fumarate) primary completion](https://sec-api.dev/pdufa/dimethyl) | BIIB | Relapsing-Remitting Multiple Sclerosis | completed | "NCT02283853 (Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-07-08 (ACTUAL); Lead Sponsor Biogen; Results First Posted 2026-05-19." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02283853)) |
| July 8, 2025 | [Pozelimab + cemdisiran primary completion](https://sec-api.dev/pdufa/pozelimab-cemdisiran) | REGN | Generalized Myasthenia Gravis | completed | "NCT05070858 (A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-07-08 (ACTUAL); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05070858)) |
| July 9, 2025 | [Rademikibart NDA/BLA submission](https://sec-api.dev/pdufa/rademikibart) | CNTB | AD in adults and adolescents | completed | "On July 9, 2025, Connect Biopharma Holdings Limited (the "Company") issued a press release announcing that the Company's collaborator and exclusive licensee in China, Simcere Pharmaceutical Co., Ltd. ("Simcere"), has submitted its New Drug Application ("NDA") for rademikibart to the National Medical Products Administration of China ("NMPA") for the treatment of atopic dermatitis ("AD") in adults and adolescents." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1835268/000162828025034551/cntb-20250709.htm)) |
| July 9, 2025 | [KB801 trial start](https://sec-api.dev/pdufa/kb801) | KRYS | neurotrophic keratitis | completed | "On July 9, 2025, Krystal Biotech, Inc. (the "Company") issued a press release announcing the first patient dosed in the Company's Phase 1/2 trial of KB801 for the treatment of neurotrophic keratitis." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1711279/000171127925000065/krys-20250709.htm)) |
| July 9, 2025 | [Bivamelagon topline data readout](https://sec-api.dev/pdufa/bivamelagon) | RYTM |  | completed, positive | "(Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced positive topline results from its Phase 2 trial evaluating bivamelagon (formerly LB54640), an investigational oral melanocortin-4 receptor (MC4R) agonist, in patients with acquired hypothalamic obesity." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649904/000110465925066724/tm2520203d1_ex99-1.htm)) |
| July 9, 2025 | [Nurix Therapeutics, Inc. earnings report](https://sec-api.dev/companies/nrix/catalysts) | NRIX |  | completed | "Nurix Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1549595/000154959525000094/nrix-20250709xexx991.htm)) |
| July 9, 2025 | [Ateganosine trial start](https://sec-api.dev/pdufa/ateganosine) | MAIA |  | completed | "July 9, 2025, the Company issued a press release announcing the first patient dosed in expansion of Phase 2 Trial for Ateganosine in advanced non-small cell lung cancer." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1878313/000164117225018398/form8-k.htm)) |
| July 9, 2025 | [Deramiocel complete response letter (CRL)](https://sec-api.dev/pdufa/deramiocel) | CAPR | cardiomyopathy associated with Duchenne muscular dystrophy | completed, complete response letter | "COMPLETE RESPONSE letter dated 07/09/2025 for BL 125842 to Capricor, Inc.." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_BLA125842_20250709.pdf%22)) |
| July 9, 2025 | [Domvanalimab primary completion](https://sec-api.dev/pdufa/domvanalimab) | RCUS |  | completed | "NCT04262856 (Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-07-09 (ACTUAL); Lead Sponsor Arcus Biosciences, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04262856)) |
| July 9, 2025 | [Cab-axl-adc primary completion](https://sec-api.dev/pdufa/cab-axl-adc) | BCAB | Non-Small-Cell Lung Cancer | completed | "NCT04681131 (CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-07-09 (ACTUAL); Lead Sponsor BioAtla, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04681131)) |
| July 9, 2025 | [ALXN1850 primary completion](https://sec-api.dev/pdufa/alxn1850) | AZN | Hypophosphatasia | completed | "NCT06079281 (Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-07-09 (ACTUAL); Lead Sponsor Alexion Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06079281)) |
| July 9, 2025 | [Tdv primary completion](https://sec-api.dev/pdufa/tdv) | TAK | Dengue Fever | completed | "NCT06741683 (A Study of Dengue Tetravalent Vaccine (TDV) in Healthy Participants in Japan): Overall Status COMPLETED; Phase PHASE2, PHASE3; Primary Completion 2025-07-09 (ACTUAL); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06741683)) |
| July 10, 2025 | [Lynozyfic (linvoseltamab) PDUFA date](https://sec-api.dev/pdufa/linvoseltamab) | REGN |  | scheduled | "•The FDA accepted for review the resubmission of the BLA for linvoseltamab, a bispecific antibody targeting BCMA and CD3, in R/R multiple myeloma, with a target action date of July 10, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/872589/000180422025000020/exhibit991q12025.htm)) |
| July 10, 2025 | [Elrexfio (elranatamab) label expansion decision](https://sec-api.dev/pdufa/elranatamab) | PFE |  | completed, approved | "BLA761345 SUPPL-3 (Efficacy): submission_status AP, submission_status_date 20250710, review_priority STANDARD; sponsor_name PFIZER INC; product ELREXFIO (ELRANATAMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761345%22)) |
| July 10, 2025 | [PF-07220060 primary completion](https://sec-api.dev/pdufa/pf-07220060) | PFE | Breast Cancer | completed | "NCT06465368 (A Study to Learn About the Study Medicine PF-07220060 Together With Letrozole Compared to Letrozole Alone in Women Post Menopause): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-07-10 (ACTUAL); Lead Sponsor Pfizer; Results First Posted 2026-07-15." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06465368)) |
| July 10, 2025 | [Motegrity (prucalopride succinate) label expansion decision](https://sec-api.dev/pdufa/prucalopride) | TAK |  | completed, approved | "NDA210166 SUPPL-4 (Efficacy): submission_status AP, submission_status_date 20250710, review_priority STANDARD; sponsor_name TAKEDA PHARMS USA; product MOTEGRITY (PRUCALOPRIDE SUCCINATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA210166%22)) |
| July 11, 2025 | [CARDAMYST (etripamil) NDA/BLA acceptance](https://sec-api.dev/pdufa/etripamil) | MIST |  | completed | "On July 11, 2025, we announced that the FDA had accepted our response to the Complete Response Letter regarding our NDA for CARDAMYST (etripamil) nasal spray for the treatment of PSVT." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1408443/000110465925067502/tm2520348-3_424b5.htm)) |
| July 11, 2025 | [CARDAMYST (etripamil) complete response letter (CRL)](https://sec-api.dev/pdufa/etripamil) | MIST | with paroxysmal supraventricular tachycardia | completed, complete response letter | "On July 11, 2025, we announced that the FDA accepted for review our response to issues raised in the CRL for CARDAMYST™ (etripamil) nasal spray, an investigational, novel therapy for the treatment of patients with paroxysmal supraventricular tachycardia." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1408443/000155837025011141/mist-20250630x10q.htm)) |
| July 11, 2025 | [Jaypirca (pirtobrutinib) primary completion](https://sec-api.dev/pdufa/pirtobrutinib) | LLY | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma | completed | "NCT05023980 (A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-07-11 (ACTUAL); Lead Sponsor Loxo Oncology, Inc.; Results First Posted 2026-09-25." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05023980)) |
| July 11, 2025 | [GOHIBIC (vilobelimab) primary completion](https://sec-api.dev/pdufa/vilobelimab) | IFRX | Pyoderma Gangrenosum | withdrawn | "NCT05964413 (Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in Ulcerative Pyoderma Gangrenosum): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-07-11 (ACTUAL); Lead Sponsor InflaRx GmbH." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05964413)) |
| July 14, 2025 | [Tab-cel (tabelecleucel) NDA/BLA submission](https://sec-api.dev/pdufa/tabelecleucel) | ATRA | cancer and autoimmune diseases, today | completed | "THOUSAND OAKS, Calif.(BUSINESS WIRE) Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that it has resubmitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for tabelecleucel (EBVALLO or tab-cel®) indicated as monotherapy for treatment of adult and pediatric patients two years of age and older with Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1604464/000119312525158719/d63996dex991.htm)) |
| July 14, 2025 | [ELEVIDYS (delandistrogene moxeparvovec) earnings report](https://sec-api.dev/pdufa/delandistrogene-moxeparvovec) | SRPT |  | completed | "In addition to the restructuring plan, the Company provided an update on activities related to the label updates underway for ELEVIDYS (delandistrogene moxeparvovec), the first and only approved gene therapy for the treatment of Duchenne muscular dystrophy and reported preliminary financial results for the quarter ended June 30, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/873303/000095017025096257/srpt-ex99_1.htm)) |
| July 14, 2025 | [Corcept NDA/BLA submission](https://sec-api.dev/pdufa/corcept) | CORT | severe endocrinologic, oncologic, metabolic and neurologic disorders | completed | "REDWOOD CITY, Calif., (July 14, 2025)  Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, has submitted a new drug application (NDA) to the U.S. Food and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1088856/000119312525158454/d940113dex991.htm)) |
| July 14, 2025 | [Lonsurf primary completion](https://sec-api.dev/pdufa/lonsurf) | BMY | Colorectal Neoplasms | withdrawn | "NCT05328908 (A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-07-14 (ACTUAL); Lead Sponsor Bristol-Myers Squibb; Results First Posted 2026-08-26." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05328908)) |
| July 14, 2025 | [AZD2693 primary completion](https://sec-api.dev/pdufa/azd2693) | AZN | Nonalcoholic Steatohepatitis | completed | "NCT05809934 (A Study to Evaluate AZD2693 in Participants Who Are Carriers of the PNPLA3 148M Risk Allele With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-07-14 (ACTUAL); Lead Sponsor AstraZeneca; Results First Posted 2026-10-28." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05809934)) |
| July 14, 2025 | [Pipe-307 dose a primary completion](https://sec-api.dev/pdufa/pipe-307) | JNJ | Relapsing Remitting Multiple Sclerosis | completed | "NCT06083753 (Study to Evaluate the Safety and Efficacy of PIPE-307 in Subjects With Relapsing-Remitting Multiple Sclerosis): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-07-14 (ACTUAL); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06083753)) |
| July 15, 2025 | [Akebia Therapeutics, Inc. PDUFA date](https://sec-api.dev/companies/akba/catalysts) | AKBA |  | scheduled | "As of July 15, 2025, there has been at least one report in which the FDA failed to meet a PDUFA goal date for approval of an NDA due to heavy workload and limited resources." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1517022/000151702226000039/akba-20260331.htm)) |
| July 15, 2025 | [Dyne Therapeutics, Inc. PDUFA date](https://sec-api.dev/companies/dyn/catalysts) | DYN |  | scheduled | "As of July 15, 2025, there has been at least one report in which the FDA failed to meet a PDUFA goal date for approval of an NDA due to heavy workload and limited resources." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1818794/000095017025099161/dyn-20250630.htm)) |
| July 15, 2025 | [Beam Therapeutics Inc. PDUFA date](https://sec-api.dev/companies/beam/catalysts) | BEAM |  | scheduled | "As of July 15, 2025, there has been at least one report in which the FDA failed to meet a PDUFA goal date for approval of a new drug application due to heavy workload and limited resources." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1745999/000095017025102393/beam-20250630.htm)) |
| July 15, 2025 | [Trevi Therapeutics, Inc. PDUFA date](https://sec-api.dev/companies/trvi/catalysts) | TRVI |  | scheduled | "As of July 15, 2025, there has been at least one report in which the FDA failed to meet a PDUFA goal date for approval of an NDA due to heavy workload and limited resources." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1563880/000095017025105066/trvi-20250630.htm)) |
| July 15, 2025 | [Kalaris Therapeutics, Inc. PDUFA date](https://sec-api.dev/companies/klrs/catalysts) | KLRS |  | scheduled | "As of July 15, 2025, there has been at least one report in which the FDA failed to meet a PDUFA goal date for approval of an NDA due to heavy workload and limited resources." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1754068/000095017025107979/klrs-20250630.htm)) |
| July 15, 2025 | [KALA BIO, Inc. PDUFA date](https://sec-api.dev/companies/kala/catalysts) | KALA |  | scheduled | "As of July 15, 2025, there has been at least one report in which the FDA failed to meet a PDUFA goal date for approval of an NDA due to heavy workload and limited resources." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1479419/000155837025010853/kala-20250630x10q.htm)) |
| July 15, 2025 | [ARVINAS, INC. PDUFA date](https://sec-api.dev/companies/arvn/catalysts) | ARVN |  | scheduled | "As of July 15, 2025, there has been at least one report in which the FDA failed to meet a PDUFA goal date for approval of an NDA due to heavy workload and limited resources." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1655759/000165575925000139/arvn-20250630.htm)) |
| July 15, 2025 | [CURIS INC PDUFA date](https://sec-api.dev/companies/cris/catalysts) | CRIS |  | scheduled | "As of July 15, 2025, there has been at least one report in which the FDA failed to meet a PDUFA goal date for approval of an NDA due to heavy workload and limited resources." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1108205/000110820525000080/cris-20250630.htm)) |
| July 15, 2025 | [Climb Bio, Inc. PDUFA date](https://sec-api.dev/companies/clym/catalysts) | CLYM |  | scheduled | "As of July 15, 2025, there has been at least one report in which the FDA failed to meet a PDUFA goal date for approval of a new drug applications (NDA) due to heavy workload and limited resources." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1768446/000095017025106916/clym-20250630.htm)) |
| July 15, 2025 | [Spero Therapeutics, Inc. PDUFA date](https://sec-api.dev/companies/spro/catalysts) | SPRO |  | scheduled | "As of July 15, 2025, there has been at least one report in which the FDA failed to meet a PDUFA goal date for approval of an NDA due to heavy workload and limited resources." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1701108/000095017025107388/spro-20250630.htm)) |
| July 15, 2025 | [Schrodinger, Inc. PDUFA date](https://sec-api.dev/companies/sdgr/catalysts) | SDGR |  | scheduled | "As of July 15, 2025, there has been at least one report in which the FDA failed to meet a PDUFA goal date for approval of an NDA due to heavy workload and limited resources." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1490978/000149097826000076/sdgr-20260930.htm)) |
| July 15, 2025 | [AZD3427 primary completion](https://sec-api.dev/pdufa/azd3427) | AZN | Pulmonary Hypertension (World Health Organization Group 2); Heart Failure | completed | "NCT05737940 (A Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Group 2): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-07-15 (ACTUAL); Lead Sponsor AstraZeneca; Results First Posted 2026-10-27." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05737940)) |
| July 16, 2025 | [FASPRO (daratumumab-hyaluronidase) FDA advisory committee meeting](https://sec-api.dev/pdufa/daratumumab-hyaluronidase) | JNJ |  | completed | "U.S. FDA Oncologic Drugs Advisory Committee votes in favor of the benefit-risk profile of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for high-risk smoldering multiple myeloma" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/200406/000020040625000170/a2025q2exhibit991.htm)) |
| July 16, 2025 | [Amneal Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/amrx/catalysts) | AMRX |  | completed | "AMNEAL REPORTS CERTAIN PRELIMINARY SECOND QUARTER 2025 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1723128/000172312825000033/amrx-q22025x8xkxpreannounc.htm)) |
| July 16, 2025 | [LUMYKRAS™ (sotorasib) primary completion](https://sec-api.dev/pdufa/sotorasib) | AMGN | Colorectal Cancer (CRC) | completed | "NCT05198934 (Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-07-16 (ACTUAL); Lead Sponsor Amgen; Results First Posted 2026-07-22." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05198934)) |
| July 17, 2025 | [Reproxalap NDA/BLA acceptance](https://sec-api.dev/pdufa/reproxalap) | ALDX | signs and symptoms of dry eye disease | completed | "On July 17, 2025, Aldeyra announced that the FDA accepted the reproxalap NDA for review and assigned a PDUFA date of December 16, 2025." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1341235/000119312526109511/aldx-20260317.htm)) |
| July 17, 2025 | [Medpace Holdings, Inc. earnings report](https://sec-api.dev/companies/medp/catalysts) | MEDP |  | completed | "Medpace Holdings, Inc. Reports Second Quarter 2025 Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1668397/000166839725000085/medp-2025721exx991.htm)) |
| July 17, 2025 | [ABBOTT LABORATORIES earnings report](https://sec-api.dev/companies/abt/catalysts) | ABT |  | completed | "Abbott Reports Second-Quarter 2025 Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1800/000162828025035135/abt-2025q2xexhibitx991.htm)) |
| July 17, 2025 | [Blenrep (belantamab mafodotin-blmf) FDA advisory committee meeting](https://sec-api.dev/pdufa/belantamab-mafodotin-blmf) | GSK |  | completed, negative | "The Committee will discuss BLA 761440, belantamab mafodotin submitted by GlaxoSmithKline LLC, for the treatment of adults with multiple myeloma in combination with bortezomib and dexamethasone in patients who have received at least one prior line of therapy; and in combination with pomalidomide and dexamethasone in patients who have received at least one prior line of therapy including lenalidomide." ([FDA advisory committee calendar](https://www.fda.gov/advisory-committees/july-17-2025-meeting-oncologic-drugs-advisory-committee-07172025)) |
| July 17, 2025 | [Elritercept trial start](https://sec-api.dev/pdufa/elritercept) | KROS | very low-, low-, or intermediate-risk MDS | completed | "On July 17, 2025, Keros Therapeutics, Inc. (the "Company") issued a press release announcing that the first patient was dosed in the Phase 3 RENEW clinical trial of elritercept in adults with transfusion-dependent anemia with very low, low, or intermediate risk myelodysplastic syndromes." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1664710/000166471025000062/kros-20250717.htm)) |
| July 17, 2025 | [DiaMedica Therapeutics Inc. interim data readout](https://sec-api.dev/companies/dmac/catalysts) | DMAC | preeclampsia | completed, positive | "Minneapolis, Minnesota - July 17, 2025 - (BUSINESS WIRE) - DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company, today announced positive interim results from Part 1a of the Phase 2 study of DM199 for the treatment of preeclampsia." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1401040/000143774925022877/ex_839667.htm)) |
| July 17, 2025 | [Pasatru (garetosmab) primary completion](https://sec-api.dev/pdufa/garetosmab) | REGN | Fibrodysplasia Ossificans Progressiva | completed | "NCT05394116 (A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-07-17 (ACTUAL); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05394116)) |
| July 18, 2025 | [RINVOQ® (upadacitinib) primary completion](https://sec-api.dev/pdufa/upadacitinib) | ABBV | Crohn's Disease (CD) | completed | "NCT02782663 (A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants With Crohn's Disease): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-07-18 (ACTUAL); Lead Sponsor AbbVie; Results First Posted 2026-08-13." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02782663)) |
| July 20, 2025 | [Dasiglucagon primary completion](https://sec-api.dev/pdufa/dasiglucagon) | NVO | Diabetes Mellitus, Type 1 | completed | "NCT06588504 (Research Study in Japan to Compare Dasiglucagon With Glucagon in Treating Very Low Levels of Blood Sugar in Asian Adults With Type 1 Diabetes and Testing of Dasiglucagon for the Same Condition in Japanese Adolescents): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-07-20 (ACTUAL); Lead Sponsor Novo Nordisk A/S; Results First Posted 2026-11-16." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06588504)) |
| July 21, 2025 | [Opdivo® (nivolumab) complete response letter (CRL)](https://sec-api.dev/pdufa/nivolumab) | REPL | advanced melanoma in July 2025 | completed, complete response letter | "The resubmission is considered by the FDA to be a complete response to the complete response letter received on July 21, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1737953/000110465925107438/tm2530417d1_ex99-1.htm)) |
| July 21, 2025 | [Neuropeptide topline data readout](https://sec-api.dev/pdufa/neuropeptide) | ALKS | narcolepsy type 1 | completed, positive | "DUBLIN, July 21, 2025 -- Alkermes plc (Nasdaq: ALKS) today announced positive topline results from the randomized double-blind treatment period of the Vibrance-1 phase 2 study evaluating alixorexton in patients with narcolepsy type 1 (NT1)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1520262/000095017025097323/alks-ex99_1.htm)) |
| July 21, 2025 | [COM701 trial start](https://sec-api.dev/pdufa/com701) | CGEN | relapsed platinum sensitive ovarian cancer | completed | "Compugen Announces First Patient Dosed in COM701 Global" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1119774/000117891325002420/exhibit_99-1.htm)) |
| July 21, 2025 | [VLA15 primary completion](https://sec-api.dev/pdufa/vla15) | PFE | Lyme Disease | completed | "NCT05634811 (Safety Study of a Vaccine to Help Protect Against Lyme Disease in Healthy Children): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-07-21 (ACTUAL); Lead Sponsor Pfizer; Results First Posted 2026-05-07." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05634811)) |
| July 21, 2025 | [Vusolimogene oderparepvec complete response letter (CRL)](https://sec-api.dev/pdufa/vusolimogene-oderparepvec) | REPL | advanced melanoma | completed, complete response letter | "COMPLETE RESPONSE letter dated 07/21/2025 for BL 125827 to Replimune, Inc.." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_BLA125827_20250721.pdf%22)) |
| July 22, 2025 | [Replimune Group, Inc. PDUFA date](https://sec-api.dev/companies/repl/catalysts) | REPL |  | scheduled | "PDUFA action date of July 22, 2025, with priority review" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1737953/000110465925005291/tm254066d1_ex99-1.htm)) |
| July 22, 2025 | [Lanreotide complete response letter (CRL)](https://sec-api.dev/pdufa/lanreotide) | AMRX |  | completed, complete response letter | "For 2025, asset impairment charges primarily related to a Specialty segment product right for which the Company significantly reduced the cash flow forecast after receipt of a complete response letter dated July 22, 2025 from the U.S. Food and Drug Administration regarding a supplemental new drug application." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1723128/000172312826000035/amrx-q32026ex991.htm)) |
| July 22, 2025 | [IQVIA HOLDINGS INC. earnings report](https://sec-api.dev/companies/iqv/catalysts) | IQV |  | completed | "IQVIA Reports Second-Quarter 2025 Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1478242/000147824225000102/iqv-q2x2025earningspressre.htm)) |
| July 22, 2025 | [Replimune Group, Inc. NDA/BLA acceptance](https://sec-api.dev/companies/repl/catalysts) | REPL |  | completed | "The FDA accepted our BLA and granted priority review with a Prescription Drug User Fee Act, or PDUFA, goal date of July 22, 2025." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1737953/000110465926093040/tm2622669-1_424b5.htm)) |
| July 22, 2025 | [Replimune Group, Inc. complete response letter (CRL)](https://sec-api.dev/companies/repl/catalysts) | REPL | advanced melanoma | completed, complete response letter | "The complaint, captioned Jboor v. Replimune Group, Inc. et al., Case No. 1:25-cv-12085-JEK, was filed shortly after the Company announced it received a complete response letter from the FDA for its RP1 BLA for the treatment of advanced melanoma on July 22, 2025 and the subsequent decline in the trading price of the Company's common stock." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1737953/000162828026067722/repl-20260930.htm)) |
| July 22, 2025 | [Obefazimod topline data readout](https://sec-api.dev/pdufa/obefazimod) | ABVX |  | completed, positive | "Paris: FR0012333284  ABVX / Nasdaq: ABVX) (Abivax or the Company), a clinical-stage biotechnology company focused on developing therapeutics that harness the bodys natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced positive topline results from its Phase 3 ABTECT-1 (Study 105) and ABTECT-2 (Study 106) 8-week induction trials evaluating its oral, first-in-class miR-124 enhancer, obefazimod (ABX464), in adult patients with moderately to severely active ulcerative colitis (UC)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1956827/000119312525162671/d56921dex991.htm)) |
| July 22, 2025 | [Opdivo® (nivolumab) PDUFA date](https://sec-api.dev/pdufa/nivolumab) | REPL |  | completed, complete response letter | "Food and Drug Administration (FDA) recently accepted the Biologics License Application (BLA) for RP1 plus nivolumab in advanced melanoma for priority review with a PDUFA date of July 22, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1737953/000110465925011851/tm256243d1_ex99-1.htm)) |
| July 23, 2025 | [Alzamend Neuro, Inc. earnings report](https://sec-api.dev/companies/alzn/catalysts) | ALZN |  | completed | "Neuro, Inc. (Nasdaq: ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), reported its financial results for the year ended April 30, 2025, which were disclosed on an annual report on Form 10-K filed on July 22, 2025, with the Securities and Exchange Commission." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1677077/000121465925010830/ex99_1.htm)) |
| July 23, 2025 | [GSK plc PDUFA date](https://sec-api.dev/companies/gsk/catalysts) | GSK |  | scheduled | "The US FDA has assigned a Prescription Drug User Fee Act action date of 23 July 2025." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1131399/000165495425001166/finalresults05-0225.htm)) |
| July 23, 2025 | [CHAMPIONS ONCOLOGY, INC. earnings report](https://sec-api.dev/companies/csbr/catalysts) | CSBR |  | completed | "Hackensack, NJ - July 23, 2025 - Champions Oncology, Inc. (Nasdaq: CSBR), a leading translational oncology research organization, today announced its financial results for the fiscal year and fourth quarter ended April 30, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/771856/000162828025035727/csbr8-k4302025exhibit991.htm)) |
| July 23, 2025 | [Otezla (apremilast) label expansion decision](https://sec-api.dev/pdufa/apremilast) | AMGN |  | completed, approved | "NDA205437 SUPPL-14 (Efficacy): submission_status AP, submission_status_date 20250723, review_priority STANDARD; sponsor_name AMGEN INC; product OTEZLA (APREMILAST)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA205437%22)) |
| July 23, 2025 | [Viking Therapeutics, Inc. earnings report](https://sec-api.dev/companies/vktx/catalysts) | VKTX |  | completed | "Viking Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1607678/000095017025097885/vktx-ex99_1.htm)) |
| July 23, 2025 | [GSK1070806 primary completion](https://sec-api.dev/pdufa/gsk1070806) | GSK | Dermatitis, Atopic | withdrawn | "NCT05999799 (A Dose Finding Study to Investigate the Safety and Effectiveness of GSK1070806 in Adult Participants With Moderate to Severe Atopic Dermatitis): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-07-23 (ACTUAL); Lead Sponsor GlaxoSmithKline; Results First Posted 2026-06-03." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05999799)) |
| July 23, 2025 | [Strensiq (asfotase alfa) primary completion](https://sec-api.dev/pdufa/asfotase-alfa) | AZN | Hypophosphatasia | completed | "NCT06079372 (Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-07-23 (ACTUAL); Lead Sponsor Alexion Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06079372)) |
| July 23, 2025 | [Amlitelimab primary completion](https://sec-api.dev/pdufa/amlitelimab) | SNY | Dermatitis Atopic | completed | "NCT06130566 (A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-07-23 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06130566)) |
| July 24, 2025 | [VIR-5525 trial start](https://sec-api.dev/pdufa/vir-5525) | VIR | Solid Tumors | completed | "On July 24, 2025, Vir Biotechnology, Inc. (the Company) issued a press release announcing the first patient dosed in the Company's Phase 1 clinical trial evaluating VIR-5525, an investigational dual-masked T-cell engager targeting EGFR (epidermal growth factor receptor)." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1706431/000162828025035847/vir-20250724.htm)) |
| July 24, 2025 | [ImmunityBio, Inc. earnings report](https://sec-api.dev/companies/ibrx/catalysts) | IBRX |  | completed | "CULVER CITY, Calif.,  July 25, 2025  ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced preliminary financial results for the fiscal quarter ended June 30, 2025, and clinical progress across its pipeline." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1326110/000119312525164789/d20571dex991.htm)) |
| July 24, 2025 | [Cipargamin primary completion](https://sec-api.dev/pdufa/cipargamin) | NVS | Severe Malaria | completed | "NCT04675931 (To Evaluate Efficacy, Safety, Tolerability and PK of Intravenous Cipargamin in Participants With Severe Plasmodium Falciparum Malaria): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-07-24 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals; Results First Posted 2026-04-09." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04675931)) |
| July 24, 2025 | [Ndec - oral decitabine-tetrahydrouridine primary completion](https://sec-api.dev/pdufa/ndec-oral-decitabine-tetrahydrouridine) | NVO | Sickle Cell Disease | completed | "NCT05405114 (Research Study Investigating How Well NDec Works in People With Sickle Cell Disease): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-07-24 (ACTUAL); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05405114)) |
| July 24, 2025 | [Nirsevimab primary completion](https://sec-api.dev/pdufa/nirsevimab) | AZN | Respiratory Syncytial Virus Infections | completed | "NCT06042049 (A Study to Assess Safety, Pharmacokinetics Anti-Drug Antibody and Anti-RSV Antibody After 2 Doses of Nirsevimab): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-07-24 (ACTUAL); Lead Sponsor AstraZeneca; Results First Posted 2026-04-16." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06042049)) |
| July 24, 2025 | [KEYTRUDA® (pembrolizumab) label expansion decision](https://sec-api.dev/pdufa/pembrolizumab) | MRK |  | completed, approved | "BLA125514 SUPPL-178 (Efficacy): submission_status AP, submission_status_date 20250724, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22)) |
| July 25, 2025 | [Merck & Co., Inc. earnings report](https://sec-api.dev/companies/mrk/catalysts) | MRK |  | completed | "USA Announces Second-Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/310158/000110465925071380/tm2521736d1_ex99-1.htm)) |
| July 25, 2025 | [Repatha (evolocumab) primary completion](https://sec-api.dev/pdufa/evolocumab) | AMGN | Coronary Heart Disease (CHD) | completed | "NCT03872401 (Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-07-25 (ACTUAL); Lead Sponsor Amgen; Results First Posted 2026-06-25." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03872401)) |
| July 25, 2025 | [Foundayo (orforglipron calcium) primary completion](https://sec-api.dev/pdufa/orforglipron) | LLY | Obesity; Overweight; Overweight or Obesity | completed | "NCT05869903 (A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-07-25 (ACTUAL); Lead Sponsor Eli Lilly and Company; Results First Posted 2026-08-14." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05869903)) |
| July 25, 2025 | [Imvt-1401 (batoclimab) primary completion](https://sec-api.dev/pdufa/imvt-1401-batoclimab) | IMVT | Graves Disease | completed | "NCT05907668 (A Proof-of-Concept Study to Assess Batoclimab in Participants With Graves' Disease): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-07-25 (ACTUAL); Lead Sponsor Immunovant Sciences GmbH; Results First Posted 2026-08-13." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05907668)) |
| July 25, 2025 | [NBI-1070770 primary completion](https://sec-api.dev/pdufa/nbi-1070770) | NBIX | Major Depressive Disorder | completed | "NCT06267846 (A Study to Evaluate the Efficacy and Safety of NBI-1070770 in Adults With Major Depressive Disorder): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-07-25 (ACTUAL); Lead Sponsor Neurocrine Biosciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06267846)) |
| July 27, 2025 | [Royalty Pharma plc PDUFA date](https://sec-api.dev/companies/rprx/catalysts) | RPRX |  | scheduled | "The FDA set a Prescription Drug User Fee Act (PDUFA) goal date of July 27, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1802768/000119312525023988/d929959dex991.htm)) |
| July 27, 2025 | [SKYTROFA (lonapegsomatropin) PDUFA date](https://sec-api.dev/pdufa/lonapegsomatropin) | ASND | with GHD | scheduled | "SKYTROFA - Approved for pediatric growth hormone deficiency (GHD) 2 - Full-year 2024 SKYTROFA revenue expected to be ~€202 million , excluding sales deductions related to prior years - sBLA submitted for the treatment of adults with GHD, with a PDUFA goal date of July 27, 2025 ® 1" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1612042/000119312525004905/d923527dex991.htm)) |
| July 28, 2025 | [Sephience™ (sepiapterin) FDA approval](https://sec-api.dev/pdufa/sepiapterin) | PTCT | children and adults living with PKU | completed, approved | "On July 28, 2025, PTC Therapeutics, Inc. (the "Company"), announced that the U.S. Food and Drug Administration ("FDA") approved Sephience™ (sepiapterin) for the treatment of children and adults living with phenylketonuria ("PKU")." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1070081/000155837025009663/tmb-20250728x8k.htm)) |
| July 28, 2025 | [ATH434 topline data readout](https://sec-api.dev/pdufa/ath434) | ATHE |  | completed, positive | "Subsequent to the period end, on 28 July 2025, Alterity announced positive positive topline data from the ATH434-202 open-label Phase 2 clinical trial in individuals with MSA." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1131343/000121390025068955/ea025072501ex99-1_alterity.htm)) |
| July 28, 2025 | [EXELIXIS, INC. earnings report](https://sec-api.dev/companies/exel/catalysts) | EXEL |  | completed | "Exelixis Announces Second Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/939767/000093976725000111/exel20250630exhibit991.htm)) |
| July 28, 2025 | [Zanzalintinib trial start](https://sec-api.dev/pdufa/zanzalintinib) | EXEL |  | completed | "We also initiated the STELLAR-311 pivotal study in advanced NET during the quarter and plan to announce an additional wave of zanzalintinib pivotal trials in the coming months." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/939767/000093976725000111/exel20250630exhibit991.htm)) |
| July 28, 2025 | [Sirturo (bedaquiline fumarate) label expansion decision](https://sec-api.dev/pdufa/bedaquiline) | JNJ |  | completed, approved | "NDA204384 SUPPL-20 (Efficacy): submission_status AP, submission_status_date 20250728, review_priority PRIORITY; sponsor_name JANSSEN THERAP; product SIRTURO (BEDAQUILINE FUMARATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA204384%22)) |
| July 28, 2025 | [NRC HEALTH earnings report](https://sec-api.dev/companies/nrc/catalysts) | NRC |  | completed | "NRC HEALTH ANNOUNCES SECOND QUARTER 2025 RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/70487/000143774925023676/ex_843665.htm)) |
| July 28, 2025 | [GeoVax Labs, Inc. earnings report](https://sec-api.dev/companies/govx/catalysts) | GOVX |  | completed | "GeoVax Reports Second Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/832489/000143774925023689/ex_843599.htm)) |
| July 28, 2025 | [Dyne Therapeutics, Inc. earnings report](https://sec-api.dev/companies/dyn/catalysts) | DYN |  | completed | "Dyne Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1818794/000095017025099184/dyn-ex99_1.htm)) |
| July 28, 2025 | [Fasenra (benralizumab) primary completion](https://sec-api.dev/pdufa/benralizumab) | AZN | Chronic Obstructive Pulmonary Disease | completed | "NCT04053634 (Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-07-28 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04053634)) |
| July 28, 2025 | [MRNA-1345 primary completion](https://sec-api.dev/pdufa/mrna-1345) | MRNA | Respiratory Syncytial Virus | completed | "NCT05127434 (A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of Age): Overall Status COMPLETED; Phase PHASE2, PHASE3; Primary Completion 2025-07-28 (ACTUAL); Lead Sponsor ModernaTX, Inc.; Results First Posted 2026-09-29." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05127434)) |
| July 28, 2025 | [TAK-341 primary completion](https://sec-api.dev/pdufa/tak-341) | TAK | Multiple System Atrophy | completed | "NCT05526391 (A Study of TAK-341 in Treatment of Multiple System Atrophy): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-07-28 (ACTUAL); Lead Sponsor Takeda; Results First Posted 2026-06-02." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05526391)) |
| July 28, 2025 | [Lipfendra (enlicitide decanoate) primary completion](https://sec-api.dev/pdufa/enlicitide-decanoate) | MRK | Hypercholesterolemia; Familial Hypercholesterolemia | completed | "NCT05952856 (A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef Lipids): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-07-28 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-08-06." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05952856)) |
| July 28, 2025 | [Claseprubart primary completion](https://sec-api.dev/pdufa/claseprubart) | DNTH | Myasthenia Gravis, Generalized | completed | "NCT06282159 (A Phase 2 Study to Evaluate DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2025-07-28 (ACTUAL); Lead Sponsor Dianthus Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06282159)) |
| July 28, 2025 | [AZD2389 primary completion](https://sec-api.dev/pdufa/azd2389) | AZN | Liver Fibrosis; Hepatic Cirrhosis | completed | "NCT06750276 (A Study to Evaluate the Safety, Tolerability, PK, and PD Effects of AZD2389 in Participants With Liver Fibrosis and Compensated Cirrhosis.): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-07-28 (ACTUAL); Lead Sponsor AstraZeneca; Results First Posted 2026-07-06." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06750276)) |
| July 29, 2025 | [INCYTE CORP earnings report](https://sec-api.dev/companies/incy/catalysts) | INCY |  | completed | "Incyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical Programs" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/879169/000087916925000100/incy-q22025xexx991.htm)) |
| July 29, 2025 | [REPLIGEN CORP earnings report](https://sec-api.dev/companies/rgen/catalysts) | RGEN |  | completed | "Repligen Reports Second Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/730272/000095017025099389/rgen-ex99_1.htm)) |
| July 29, 2025 | [Kebilidi (eladocagene exuparvovec) PDUFA date](https://sec-api.dev/pdufa/eladocagene-exuparvovec) | PTCT | AADC deficiency | scheduled | "o Kebilidi (eladocagene exuparvovec-tneq) gene therapy for the treatment of AADC deficiency in the U.S., approved in November 2024 o Sepiapterin for children and adults with PKU, with a target regulatory action date of July 29, 2025 o Vatiquinone for children and adults with Friedreich's ataxia, granted priority review with a target regulatory action date of August 19, 2025 o Translarna for nmDMD" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1070081/000107008125000011/tmb-20250227xex99d1.htm)) |
| July 29, 2025 | [Kiniksa Pharmaceuticals International, plc earnings report](https://sec-api.dev/companies/knsa/catalysts) | KNSA |  | completed | "Pharmaceuticals Reports Second Quarter 2025 Financial Results and Recent Portfolio Execution" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1730430/000110465925071413/tm2521890d1_ex99-1.htm)) |
| July 29, 2025 | [UniQure N.V. earnings report](https://sec-api.dev/companies/qure/catalysts) | QURE |  | completed | "Exhibit 99.1 uniQure Announces Second Quarter 2025 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590560/000155837025009692/qure-20250729xex99d1.htm)) |
| July 29, 2025 | [CRESCENT BIOPHARMA, INC. earnings report](https://sec-api.dev/companies/cbio/catalysts) | CBIO |  | completed | "Crescent Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1253689/000162828025036846/pressrelease-q22025.htm)) |
| July 29, 2025 | [Alkermes plc. earnings report](https://sec-api.dev/companies/alks/catalysts) | ALKS |  | completed | "Alkermes plc Reports Second Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1520262/000095017025099382/alks-ex99_1.htm)) |
| July 29, 2025 | [Modzatinib topline data readout](https://sec-api.dev/pdufa/modzatinib) | ACRS | moderate-to-severe AD | completed, positive | "WAYNE, Pa., July 29, 2025 -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced positive top-line results from its open-label, single-arm Phase 2a trial of ATI-2138, a potent and selective investigational oral covalent inhibitor of interleukin-2-inducible T cell kinase (ITK) and Janus kinase 3 (JAK3), in 14 patients with moderate-to-severe atopic dermatitis (AD)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1557746/000155837025009739/acrs-20250729xex99d2.htm)) |
| July 29, 2025 | [Fulcrum Therapeutics, Inc. earnings report](https://sec-api.dev/companies/fulc/catalysts) | FULC |  | completed | "Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1680581/000095017025099404/fulc-ex99_1.htm)) |
| July 29, 2025 | [Cingulate Inc. PDUFA date](https://sec-api.dev/companies/cing/catalysts) | CING |  | scheduled | "On July 29, 2025, we received a PDUFA (Prescription Drug User Fee Act)" ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1862150/000164117225024744/form10-q.htm)) |
| July 29, 2025 | [Sephience™ (sepiapterin) PDUFA date](https://sec-api.dev/pdufa/sepiapterin) | PTCT |  | completed, approved | "- Positive CHMP opinion for Sephience™ (sepiapterin) received in April 2025, NDA review remains on track for July 29, 2025 PDUFA date -" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1070081/000107008125000018/tmb-20250506xex99d1.htm)) |
| July 29, 2025 | [Cardiff Oncology, Inc. earnings report](https://sec-api.dev/companies/crdf/catalysts) | CRDF |  | completed | "Cardiff Oncology Reports Second Quarter 2025 Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1213037/000095017025099631/crdf-ex99_1.htm)) |
| July 29, 2025 | [DBV Technologies S.A. earnings report](https://sec-api.dev/companies/dbvt/catalysts) | DBVT |  | completed | "DBV Technologies Reports Second Quarter and Half-Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1613780/000119312525168148/d945712dex991.htm)) |
| July 29, 2025 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Advanced Hepatocellular Carcinoma | completed | "NCT04740307 (Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-07-29 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-06-23." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04740307)) |
| July 29, 2025 | [Opdivo® (nivolumab) primary completion](https://sec-api.dev/pdufa/nivolumab) | BMY | Clear Cell Renal Cell Carcinoma | completed | "NCT04810078 (A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-07-29 (ACTUAL); Lead Sponsor Bristol-Myers Squibb; Results First Posted 2026-09-22." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04810078)) |
| July 29, 2025 | [GSK1070806 primary completion](https://sec-api.dev/pdufa/gsk1070806) | GSK | Dermatitis, Atopic | withdrawn | "NCT06447506 (Long-Term Study (AtDvance) to Evaluate GSK1070806 in Atopic Dermatitis.): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-07-29 (ACTUAL); Lead Sponsor GlaxoSmithKline; Results First Posted 2026-06-16." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06447506)) |
| July 29, 2025 | [LY3549492 primary completion](https://sec-api.dev/pdufa/ly3549492) | LLY | Obesity; Overweight; Type 2 Diabetes | withdrawn | "NCT07030868 (A Study of LY3549492 in Adults With Obesity or Overweight With Type 2 Diabetes): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-07-29 (ACTUAL); Lead Sponsor Eli Lilly and Company; Results First Posted 2026-08-31." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07030868)) |
| July 30, 2025 | [Wave Life Sciences, Inc. earnings report](https://sec-api.dev/companies/wve/catalysts) | WVE |  | completed | "Wave Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1631574/000119312525168644/d157278dex991.htm)) |
| July 30, 2025 | [Coya Therapeutics, Inc. PDUFA date](https://sec-api.dev/companies/coya/catalysts) | COYA |  | scheduled | "On July 29, 2025, the FDA informed Coya that due to the FDA's present workload and lack of resources, they are unable to meet its initial review goal date for the IND of July 30, 2025." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1835022/000119312525168115/d14950d8k.htm)) |
| July 30, 2025 | [NEUROCRINE BIOSCIENCES INC earnings report](https://sec-api.dev/companies/nbix/catalysts) | NBIX |  | completed | "Neurocrine Biosciences Reports Second Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/914475/000091447525000157/q2-2025xearningsrelease.htm)) |
| July 30, 2025 | [AMARIN CORP PLCUK earnings report](https://sec-api.dev/companies/amrn/catalysts) | AMRN |  | completed | "Amarin Reports Second Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/897448/000095017025099878/amrn-ex99_1.htm)) |
| July 30, 2025 | [Bausch Health Companies Inc. earnings report](https://sec-api.dev/companies/bhc/catalysts) | BHC |  | completed | "BAUSCH HEALTH ANNOUNCES SECOND QUARTER 2025 RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/885590/000088559025000030/ex991-q2x2025.htm)) |
| July 30, 2025 | [IONIS PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/ions/catalysts) | IONS |  | completed | "Ionis reports second quarter 2025 financial results and highlights progress on key programs" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/874015/000114036125027949/ef20052929_ex99-1.htm)) |
| July 30, 2025 | [LENZ Therapeutics, Inc. earnings report](https://sec-api.dev/companies/lenz/catalysts) | LENZ |  | completed | "LENZ Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1815776/000181577625000054/a991q225pressrelease.htm)) |
| July 30, 2025 | [GSK plc FDA advisory committee meeting](https://sec-api.dev/companies/gsk/catalysts) | GSK |  | completed | "This follows the US FDA Oncologic Drugs Advisory Committee (ODAC) vote against the overall benefit/risk profile at the proposed dosage of" ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1131399/000165495425008641/a0713t-gskplc2ndquarterre.htm)) |
| July 30, 2025 | [Ordspono™ (odronextamab) PDUFA date](https://sec-api.dev/pdufa/odronextamab) | REGN |  | completed, complete response letter | "•The FDA accepted for review the resubmission of the BLA for odronextamab, a bispecific antibody targeting CD20 and CD3, in relapsed/refractory (R/R) follicular lymphoma, with a target action date of July 30, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/872589/000180422025000020/exhibit991q12025.htm)) |
| July 30, 2025 | [TEVA PHARMACEUTICAL INDUSTRIES LTD earnings report](https://sec-api.dev/companies/teva/catalysts) | TEVA |  | completed | "TEL AVIV, Israel, July 30, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the quarter ended June 30, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/818686/000117184325004808/exh_991.htm)) |
| July 30, 2025 | [Biktarvy (bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate) label expansion decision](https://sec-api.dev/pdufa/bictegravir-emtricitabine-tenofovir-alafenamide) | GILD |  | completed, approved | "NDA210251 SUPPL-23 (Efficacy): submission_status AP, submission_status_date 20250730, review_priority STANDARD; sponsor_name GILEAD SCIENCES INC; product BIKTARVY (BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA210251%22)) |
| July 30, 2025 | [Degevma (denosumab-adet) complete response letter (CRL)](https://sec-api.dev/pdufa/denosumab-adet) | TEVA |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_BLA761385_20250730.pdf%22)) |
| July 30, 2025 | [REGENERON PHARMACEUTICALS, INC. PDUFA date](https://sec-api.dev/companies/regn/catalysts) | REGN |  | scheduled | "-FDA decision on BLA for relapsed/refractory FL (target action date of July 30, 2025)" ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/872589/000180422025000022/regn-20250331.htm)) |
| July 30, 2025 | [UNITED THERAPEUTICS Corp earnings report](https://sec-api.dev/companies/uthr/catalysts) | UTHR |  | completed | "United Therapeutics Corporation Reports Record Second Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1082554/000162828025036543/uthrq22025-ex991.htm)) |
| July 30, 2025 | [Soticlestat primary completion](https://sec-api.dev/pdufa/soticlestat) | TAK | Epilepsy; Dravet Syndrome (DS); Lennox-Gastaut Syndrome (LGS) | withdrawn | "NCT03635073 (A Study of Soticlestat in Adults and Children With Rare Epilepsies): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-07-30 (ACTUAL); Lead Sponsor Takeda; Results First Posted 2026-03-19." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03635073)) |
| July 30, 2025 | [MK-6194 primary completion](https://sec-api.dev/pdufa/mk-6194) | MRK | Systemic Lupus Erythematosus | withdrawn | "NCT06161116 (Efficacy and Safety of MK-6194 in Adult Participants With Systemic Lupus Erythematosus (MK-6194-006)): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-07-30 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-08-10." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06161116)) |
| July 30, 2025 | [Ordspono™ (odronextamab) complete response letter (CRL)](https://sec-api.dev/pdufa/odronextamab) | REGN |  | completed, complete response letter | "•On July 30, 2025, the FDA issued a Complete Response Letter (CRL) for the BLA for odronextamab, a bispecific antibody targeting CD20 and CD3, in relapsed/refractory follicular lymphoma after two or more lines of systemic therapy, which was also impacted by the Catalent Indiana LLC site inspection (as described above)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/872589/000087258925000017/exhibit991q22025.htm)) |
| July 31, 2025 | [AGIOS PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/agio/catalysts) | AGIO |  | completed | "Agios Reports Second Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1439222/000143922225000087/agio-073125xfyxex991earnin.htm)) |
| July 31, 2025 | [IONIS PHARMACEUTICALS INC topline data readout](https://sec-api.dev/companies/ions/catalysts) | IONS |  | scheduled | "Ionis will be initiating a quiet period starting July 31, 2025, as the Company plans to announce the topline results from both the CORE and CORE2 studies simultaneously." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/874015/000114036125027949/ef20052929_ex99-1.htm)) |
| July 31, 2025 | [Telisotuzumab vedotin FDA approval](https://sec-api.dev/pdufa/telisotuzumab-vedotin) | ABBV |  | completed, approved | "•AbbVie announced that Emrelis (telisotuzumab vedotin-tllv) was granted accelerated approval by the FDA for the treatment of adult patients with locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression who have received a prior systemic therapy." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1551152/000155115225000036/abbv-20250630xexhibit991.htm)) |
| July 31, 2025 | [Glecaprevir label expansion decision](https://sec-api.dev/pdufa/glecaprevir) | ABBV |  | completed, approved | "•AbbVie announced the FDA approved a label expansion for Mavyret (glecaprevir/pibrentasvir), an oral pangenotypic direct acting antiviral (DAA) therapy." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1551152/000155115225000036/abbv-20250630xexhibit991.htm)) |
| July 31, 2025 | [Vericel Corp earnings report](https://sec-api.dev/companies/vcel/catalysts) | VCEL |  | completed | "Vericel Reports Second Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/887359/000162828025036854/ex991earningsreleaseq22025.htm)) |
| July 31, 2025 | [Supernus, Inc. earnings report](https://sec-api.dev/companies/supn/catalysts) | SUPN |  | completed | "Indivior Reports Second Quarter 2025 Financial Results and Raises FY 2025 Financial Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1625297/000119312525169947/d908304dex991.htm)) |
| July 31, 2025 | [AbbVie Inc. earnings report](https://sec-api.dev/companies/abbv/catalysts) | ABBV |  | completed | "AbbVie Reports Second-Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1551152/000155115225000036/abbv-20250630xexhibit991.htm)) |
| July 31, 2025 | [RINVOQ® (upadacitinib) FDA approval](https://sec-api.dev/pdufa/upadacitinib) | ABBV | with giant cell arteritis | completed, approved | "•AbbVie announced the U.S. Food and Drug Administration (FDA) approved Rinvoq (upadacitinib) as the first oral Janus Kinase (JAK) inhibitor approved for the treatment of adults with giant cell arteritis (GCA)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1551152/000155115225000036/abbv-20250630xexhibit991.htm)) |
| July 31, 2025 | [BRISTOL MYERS SQUIBB CO earnings report](https://sec-api.dev/companies/bmy/catalysts) | BMY |  | completed | "Bristol Myers Squibb Reports Second Quarter Financial Results for 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/14272/000001427225000129/a2025q2ex991-filing.htm)) |
| July 31, 2025 | [Cingulate Inc. NDA/BLA submission](https://sec-api.dev/companies/cing/catalysts) | CING | ADHD in children and adults | completed | "July 31, 2025, the Company submitted its NDA to the FDA for CTx-1301 (dexmethylphenidate), the Company's lead asset for the treatment of ADHD." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1862150/000164117225022360/form8-k.htm)) |
| July 31, 2025 | [CMND-100 FDA approval](https://sec-api.dev/pdufa/cmnd-100) | CMND |  | completed, approved | "2024, the Company announced that it was granted approval by the Israeli Ministry of Health and by the FDA, respectively to initiate its first-in-human Phase I/IIa clinical trial with CMND-100 in patients suffering from AUD." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1892500/000121390025086821/ea025617001ex99-2_clearmind.htm)) |
| July 31, 2025 | [COMPASS Pathways plc earnings report](https://sec-api.dev/companies/cmps/catalysts) | CMPS |  | completed | "Compass Pathways Announces Second Quarter 2025 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1816590/000181659025000103/q22025pressrelease.htm)) |
| July 31, 2025 | [OPKO HEALTH, INC. earnings report](https://sec-api.dev/companies/opk/catalysts) | OPK |  | completed | "OPKO Health Reports Second Quarter 2025 Business Highlights and Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/944809/000095017025100891/opk-ex99_1.htm)) |
| July 31, 2025 | [Aurinia Pharmaceuticals Inc. earnings report](https://sec-api.dev/companies/auph/catalysts) | AUPH |  | completed | "Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1600620/000160062025000090/exhibit991_q22025earningsr.htm)) |
| July 31, 2025 | [Joenja® (leniolisib) NDA/BLA submission](https://sec-api.dev/pdufa/leniolisib) | PHAR | children aged 4 to 11 years diagnosed with APDS | completed | "On July 31, 2025, we submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for leniolisib for the treatment of children aged 4 to 11 years diagnosed with APDS." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1828316/000182831625000049/a2025q3pressrelease.htm)) |
| July 31, 2025 | [LNZ100 FDA approval](https://sec-api.dev/pdufa/lnz100) | LENZ | presbyopia in adults | completed, approved | "•Announced FDA approval of VIZZ for the treatment of presbyopia on July 31, 2025 as the first and only aceclidine-based eye drop approved to improve near vision in adults with presbyopia, a condition impacting approximately 128 million adults in the United States." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1815776/000181577625000069/a991q325pressrelease.htm)) |
| July 31, 2025 | [Focalin (focalin) NDA/BLA submission](https://sec-api.dev/pdufa/focalin) | CING |  | completed | "Additionally, based on this guidance, submitted the NDA for CTx-1301 on July 31, 2025 under the Section 505(b)(2) pathway with Focalin® XR as the reference listed drug, using its efficacy and safety data on file with the FDA as a basis for approval, together with bioavailability/bioequivalence data and efficacy/safety data from our CTx-1301 clinical program." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1862150/000149315226010882/form10-k.htm)) |
| July 31, 2025 | [NATURES SUNSHINE PRODUCTS INC earnings report](https://sec-api.dev/companies/natr/catalysts) | NATR |  | completed | "Nature's Sunshine Reports Second Quarter 2025 Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/275053/000162828025037004/natrq22025earningsrelease.htm)) |
| July 31, 2025 | [Corcept earnings report](https://sec-api.dev/pdufa/corcept) | CORT |  | completed | "Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1088856/000162828025036999/exhibit991pressrelease07-3.htm)) |
| July 31, 2025 | [ALNYLAM PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/alny/catalysts) | ALNY |  | completed | "Alnylam Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Period Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1178670/000117867025000089/alny2025q2earningsrelease.htm)) |
| July 31, 2025 | [Alhemo (concizumab) FDA approval](https://sec-api.dev/pdufa/concizumab) | NVO |  | completed, approved | "BLA761428 ORIG-1 (Type 9 - New indication submitted as distinct BLA, consolidated): submission_status AP, submission_status_date 20250731, review_priority STANDARD; sponsor_name NOVO NORDISK INC; product ALHEMO (CONCIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761428%22)) |
| July 31, 2025 | [Release (release) NDA/BLA submission](https://sec-api.dev/pdufa/release) | CING |  | completed | "July 31, 2025, Cingulate submitted its NDA to the FDA for CTx-1301, a novel, extended-release tablet formulation of dexmethylphenidate designed to deliver a fast onset, entire active-day efficacy, and a smooth pharmacokinetic profile with a single dose, addressing major limitations of current ADHD therapies." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1862150/000164117225024741/ex99-1.htm)) |
| July 31, 2025 | [Vanda Pharmaceuticals Inc. earnings report](https://sec-api.dev/companies/vnda/catalysts) | VNDA |  | completed | "Vanda Pharmaceuticals Reports Second Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1347178/000162828025036843/vnda8-k7312025exhibit991.htm)) |
| July 31, 2025 | [BIOGEN INC. earnings report](https://sec-api.dev/companies/biib/catalysts) | BIIB |  | completed | "Biogen reports strong second quarter 2025 results and increases full year 2025 guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/875045/000087504525000035/exhibit991-q22025pressrele.htm)) |
| July 31, 2025 | [Leqvio (inclisiran sodium) label expansion decision](https://sec-api.dev/pdufa/inclisiran) | NVS |  | completed, approved | "NDA214012 SUPPL-16 (Efficacy): submission_status AP, submission_status_date 20250731, review_priority STANDARD; sponsor_name NOVARTIS; product LEQVIO (INCLISIRAN SODIUM)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA214012%22)) |
| July 31, 2025 | [Rocatinlimab primary completion](https://sec-api.dev/pdufa/rocatinlimab) | AMGN | Atopic Dermatitis | completed | "NCT05633355 (A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-07-31 (ACTUAL); Lead Sponsor Amgen; Results First Posted 2026-07-24." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05633355)) |
| July 31, 2025 | [Botox primary completion](https://sec-api.dev/pdufa/botox) | ABBV | Masseter Muscle Prominence | completed | "NCT06137287 (A Study to Assess Adverse Events and Change of Masseter Muscle Prominence Using BOTOX Injections in Adult Participants): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-07-31 (ACTUAL); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06137287)) |

Other months: https://sec-api.dev/fda-calendar/2025-06 , https://sec-api.dev/fda-calendar/2025-08. Calendar: https://sec-api.dev/fda-calendar

## Feeds and downloads

- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "PDUFA dates July 2025: FDA calendar and catalysts." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/fda-calendar/2025-07

```bibtex
@misc{secapidev_fda_calendar_2025_07_20261116,
  title        = {PDUFA dates July 2025: FDA calendar and catalysts},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/fda-calendar/2025-07}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_fda_calendar_2025_07_20261116","title":"PDUFA dates July 2025: FDA calendar and catalysts","publisher":"sec-api.dev","URL":"https://sec-api.dev/fda-calendar/2025-07","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
